Document is current
Any future updates will be listed below
-
Authors
Akbari, Parsa
Sosina, Olukayode A. https://orcid.org/0000-0003-2120-0338
Bovijn, Jonas
Landheer, Karl https://orcid.org/0000-0001-5012-3007
Nielsen, Jonas B.
Kim, Minhee
Aykul, Senem https://orcid.org/0000-0001-7250-2913
De, Tanima
Haas, Mary E. https://orcid.org/0000-0002-2816-9268
Hindy, George
Lin, Nan
Dinsmore, Ian R.
Luo, Jonathan Z.
Hectors, Stefanie
Geraghty, Benjamin
Germino, Mary
Panagis, Lampros
Parasoglou, Prodromos
Walls, Johnathon R.
Halasz, Gabor
Atwal, Gurinder S.
,
Della Gatta, Giusy
,
Jones, Marcus
LeBlanc, Michelle G.
Still, Christopher D.
Carey, David J.
Giontella, Alice
Orho-Melander, Marju https://orcid.org/0000-0002-3578-2503
Berumen, Jaime https://orcid.org/0000-0001-6707-3317
Kuri-Morales, Pablo
Alegre-Díaz, Jesus https://orcid.org/0000-0001-9390-3871
Torres, Jason M.
Emberson, Jonathan R. https://orcid.org/0000-0001-7792-9422
Collins, Rory
Rader, Daniel J. https://orcid.org/0000-0002-9245-9876
Zambrowicz, Brian https://orcid.org/0000-0001-8831-0406
Murphy, Andrew J. https://orcid.org/0000-0003-4152-4081
Balasubramanian, Suganthi
Overton, John D.
Reid, Jeffrey G. https://orcid.org/0000-0001-8645-4713
Shuldiner, Alan R. https://orcid.org/0000-0001-9921-4305
Cantor, Michael
Abecasis, Goncalo R. https://orcid.org/0000-0003-1509-1825
Ferreira, Manuel A. R. https://orcid.org/0000-0001-9059-1825
Sleeman, Mark W.
Gusarova, Viktoria
Altarejos, Judith
Harris, Charles
Economides, Aris N. https://orcid.org/0000-0002-6508-8942
Idone, Vincent
Karalis, Katia
Della Gatta, Giusy
Mirshahi, Tooraj https://orcid.org/0000-0002-0754-3820
Yancopoulos, George D.
Melander, Olle
Marchini, Jonathan https://orcid.org/0000-0003-0610-8322
Tapia-Conyer, Roberto https://orcid.org/0000-0003-3814-2904
Locke, Adam E. https://orcid.org/0000-0001-6227-198X
Baras, Aris https://orcid.org/0000-0002-6830-3396
Verweij, Niek
Lotta, Luca A. https://orcid.org/0000-0002-2619-5956
-
Funding
Funding for this research was provided by:
Regeneron Pharmaceuticals
- License Information
-
More Information
Article History
Received: 8 February 2022
Accepted: 28 July 2022
First Online: 23 August 2022
Competing interests
: Regeneron authors receive salary from and own options and/or stock of the company. G.D.Y is the Chief Scientific Officer and member of the Board of Directors at Regeneron Pharmaceuticals; A.J.M is an Executive Officer of Regeneron Pharmaceuticals. L.A.L., P.A., O.S., M.A.R.F., and A.B. are inventors on provisional patent applications (63/233,258 and 63/274,595), U.S. non-provisional applications (17/549,692, and 17/711,137), and PCT international application (PCT/US21/63150) submitted by RGC relating to <i>INHBE</i> genetics. N.V., O.S., P.A., A.L., A.B., and L.A.L. are inventors on U.S. non-provisional applications (17/740,382), and PCT international application (PCT/US22/28415) submitted by RGC relating to <i>PDE3B</i> genetics. Other co-authors did not declare competing interests.
